
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune Inc. is strategically positioned to capitalize on the market potential for metabolic dysfunction-associated steatohepatitis (MASH) due to the promising characteristics of its lead candidate, pemvidutide, which offers a dual GLP-1/glucagon mechanism that enhances tolerability and metabolic improvement. Recent industry activity, such as Novo's acquisition of Akero Therapeutics, signals a growing recognition of the need for innovative treatments in the MASH sector, thereby validating pemvidutide’s strategic fit within this evolving landscape. The company's leadership team is enhancing its capabilities ahead of significant clinical milestones, which could further bolster investor confidence and support a broad therapeutic reach in addressing MASH across varying patient stages.
Bears say
The negative outlook on Altimmune's stock is primarily driven by significant clinical development risks associated with pemvidutide, which is still in the early stages of testing and may face challenges in demonstrating efficacy and safety. Additionally, competitive pressures in the biopharmaceutical industry could hamper the company's market entry and commercialization efforts, potentially affecting future revenue generation. Furthermore, ongoing uncertainties related to reimbursement, pricing strategies, and external factors such as the impact of COVID-19 and geopolitical tensions may adversely influence investor confidence and market performance.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares